CL2017001292A1 - 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 - Google Patents
4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139Info
- Publication number
- CL2017001292A1 CL2017001292A1 CL2017001292A CL2017001292A CL2017001292A1 CL 2017001292 A1 CL2017001292 A1 CL 2017001292A1 CL 2017001292 A CL2017001292 A CL 2017001292A CL 2017001292 A CL2017001292 A CL 2017001292A CL 2017001292 A1 CL2017001292 A1 CL 2017001292A1
- Authority
- CL
- Chile
- Prior art keywords
- gpr139
- benzotraizines
- modulators
- dihydro
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100021198 Chemerin-like receptor 2 Human genes 0.000 abstract 1
- 101000750094 Homo sapiens Chemerin-like receptor 2 Proteins 0.000 abstract 1
- 101000996780 Homo sapiens Probable G-protein coupled receptor 139 Proteins 0.000 abstract 1
- 102100033836 Probable G-protein coupled receptor 139 Human genes 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082539P | 2014-11-20 | 2014-11-20 | |
| US201562184729P | 2015-06-25 | 2015-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001292A1 true CL2017001292A1 (es) | 2018-02-16 |
Family
ID=55022667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001292A CL2017001292A1 (es) | 2014-11-20 | 2017-05-19 | 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 |
Country Status (40)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
| US12042496B2 (en) | 2018-10-16 | 2024-07-23 | The University Of Florida Research Foundation, Incorporated | Methods related to opioid therapeutics |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| CA3150508A1 (en) | 2019-09-16 | 2021-03-25 | Holger Monenschein | Azole-fused pyridazin-3(2h)-one derivatives |
| WO2021127459A1 (en) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| WO2021224680A1 (en) * | 2020-05-08 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Substituted benzotriazinone metabolites of a gpr139 agonist |
| US20230310441A1 (en) * | 2020-09-21 | 2023-10-05 | Takeda Pharmaceutical Company | Treatment for schizophrenia |
| US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
| CN116693536A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| CN116693545A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
| WO2024102802A1 (en) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zelatriazin for the treatment of depression |
| WO2025119351A1 (zh) * | 2023-12-08 | 2025-06-12 | 深圳湾实验室 | Gpr139激动剂 |
| CN120424068A (zh) * | 2024-02-02 | 2025-08-05 | 上海科技大学 | 稠杂环类化合物与其制备方法、药物组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794726A (en) * | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
| US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| EP0315390B1 (en) | 1987-11-04 | 1994-07-20 | Beecham Group Plc | Novel 4-oxobenzotriazines and 4-oxoquinazolines |
| JP4550811B2 (ja) | 2003-06-09 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | パピローマウイルスのインヒビター |
| CA2533824A1 (en) | 2003-07-31 | 2005-02-10 | Irm, Llc | Bicyclic compounds and compositions as pdf inhibitors |
| FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| AR058705A1 (es) | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| KR101115891B1 (ko) * | 2007-03-23 | 2012-02-13 | 에프. 호프만-라 로슈 아게 | 아자-피리도피리미딘온 유도체 |
| EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| JP2016515138A (ja) * | 2013-03-14 | 2016-05-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｇｐｒ１３９の生理的リガンド |
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920B1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001292A1 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 | |
| CL2017001171A1 (es) | Peptidos macrocíclicos útiles como inmunomoduladores | |
| CL2019001224A1 (es) | Composiciones de células t con car anti--bcma. | |
| CL2017001393S1 (es) | Automovil | |
| CL2017001185S1 (es) | Automovil | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| MX385915B (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| ECSP17023281A (es) | Inhibidores de mk2 y sus usos | |
| EA201792443A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| CL2018000375A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| EP3519578A4 (en) | COMPOSITIONS FOR TRANSFECTING TYPES OF RESISTANT CELLS | |
| CR20170005A (es) | Derivados de insoindolina | |
| MX2020006297A (es) | Variantes de cd19. | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| CL2017000152A1 (es) | Derivados de isoindolinona | |
| UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
| DK3377094T3 (da) | Virulenssvækkede bakterier til behandling af ondartede solide tumorer | |
| CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
| MX2015010728A (es) | Metodos y composiciones para el tratamiento de leucemia. |